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Abstract: The Translational Genomics Core (TGC) at Partners Personalized Medicine (PPM) serves as
a fee-for-service core laboratory for Partners Healthcare researchers, providing access to technology
platforms and analysis pipelines for genomic, transcriptomic, and epigenomic research projects.
The interaction of the TGC with various components of PPM provides it with a unique infrastructure
that allows for greater IT and bioinformatics opportunities, such as sample tracking and data
analysis. The following article describes some of the unique opportunities available to an academic
research core operating within PPM, such the ability to develop analysis pipelines with a dedicated
bioinformatics team and maintain a flexible Laboratory Information Management System (LIMS)
with the support of an internal IT team, as well as the operational challenges encountered to respond
to emerging technologies, diverse investigator needs, and high staff turnover. In addition, the
implementation and operational role of the TGC in the Partners Biobank genotyping project of over
25,000 samples is presented as an example of core activities working with other components of PPM.
Keywords: translational genomics core; academic core facility; genomics services; genotyping;
seamless workflows
1. Introduction
Technological and analytical advancements in genomics and decreasing cost of sequencing and
array-based platforms in recent years are a key catalyst in the exponential growth of translational
research initiatives and broader integration of clinical genetic testing. Most notably, next-generation
sequencing (NGS) technologies have enhanced the capabilities of researchers and clinical laboratories
to identify and characterize markers of disease in pursuit of personalized medicine. More recently
developed technologies, such as NGS, as well as established platforms, such as array-based
technologies, require significant laboratory infrastructure and operational expertise to maximize
their utility, and therefore, are often aggregated in core facilities at academic medical institutions. In its
commitment to advancing medical genomics research and its integration into clinical practice, Partners
Healthcare Personalized Medicine (PPM) established the Translational Genomics Core (TGC) as part of
its center to provide access and expertise of leading technologies to academic clinical and translational
researchers at Partners Healthcare.
The TGC offers end-to-end technical and analytical expertise and services across several leading
platforms that support genomic, transcriptomic and epigenomic studies (Table 1). All platforms and
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assays performed at the TGC are validated and optimized on automation instruments to provide
reproducible, high quality, and high-throughput sample processing and data generation. In addition,
the core is responsible for the evaluation and development of novel platforms and assays to further
research programs at Partners Healthcare. Alongside its role as a core facility to researchers, the TGC
is integrated into the initiatives and operations of other components within Partners Personalized
Medicine (described in “An overview of Partners Personalized Medicine at Partners Healthcare” in this
issue). As a result of these interactions, the TGC enjoys a synergistic relationship with these different
components that have translated into unique opportunities for the center and Partners researchers.
The following describes the role and operations of the TGC within the center and across the Partners
Healthcare research community.
Table 1. Platforms and services at the Translational Genomics Core.
Technology Platforms
Next Generation Sequencing (NGS) Illumina HiSeq 2500 instrumentIllumina MiSeq instrument
Array-based platforms Illumina iScan System (Infinium BeadChip)Affymetrix GeneChip Scanner
Services
Genomic analysis
Next generation sequencing:
‚ Whole genome sequencing (WGS)
‚ Whole exome sequencing (WES)
‚ Targeted gene panel sequencing (hybrid capture method or
amplicon enrichment method)
‚ Metagenomic analysis: 16S rRNA gene microbial profiling
Array based genotyping:
‚ Standard or custom arrays (500,000–5,000,000 SNPs)
Transcriptome analysis
Next generation sequencing:
‚ Whole transcriptome sequencing (RNAseq)
‚ 3’ differential gene expression (DGEseq)
‚ Small RNA and miRNA analysis (Small RNAseq)
Array based expression profiling
Whole transcript expression and analysis
3’ expression profiling (polyA transcript profiling)
miRNA profiling
Methylation analysis
Next generation sequencing:
‚ Reduced Representation Bisulfite Sequencing (RRBS)
‚ Whole-Genome Bisulfite Sequencing (WGBS)
‚ Targeted Bisulfite Sequencing
Array-based methylation analysis
Bisulfite converted CpG locus genotyping (~485,000 CpG targets)
2. Supporting Partners Investigators
Over the past year, the Translational Genomics Core has served approximately 75 investigators to
help them achieve their research goals through access to genomics platforms and services in Table 1,
providing end-to-end processing and analysis of research samples. These services are offered to
Partners Healthcare researchers with institutional, grant, or commercial funding on a first-come
first-serve basis. More than 11,000 samples were submitted to the TGC for processing across the
various platforms offered. Of all samples types submitted, approximately 75% were DNA, and the rest
were RNA, PCR product, or pre-made libraries. The majority of samples received for processing were
for genotyping and library construction and NGS sequencing services. Of the almost 5000 samples
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processed on the Infinium platform for either genotyping or methylation this year, about half were
for the Partners Biobank on Illumina’s Multi-Ethnic Consortium Genotyping Array (MEGArray) chip.
A breakdown of the types of samples submitted for the various services can be viewed below (Figure 1).J. Pers. Med. 2016, 6, 10 3 of 9 
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investigators and companies and developing new technologies in the lab. The disease areas studied by
Partners investi ators are vast so many different methods and platforms are required to support this
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services utilized by investigators can be viewed in Figure 2.
Table 2. Representative list of 10 disease areas and –omics platforms for translational/clinical research
projects studied by 75 Partners investigators over the past year illustrating broad range of clinical
research activities supported by the TGC.
Disease Areas Platform
Asthma Expression Analysis, Methlyation
Chronic obstructive pulmonary disease (COPD) RNASeq
Rheumatoid arthritis (RA) Targeted Gene Panel
Thoracic Cancer Exome Sequencing, Expression Analysis
HIV Integration Amplicon Sequencing
Coronary artery disease (CHD) Exome Sequencing
Parkinson’s/Alzheimer’s Disease Amplicon Sequencing
Myopathies Targeted Gene Panel
Hypohidrotic ectodermal dysplasia 3’DGE RNASeq
Diet effects on gut microflora 16S Microbiome rRNA Sequencing
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3. Integration of Core Operations through LIMS
At the foundation of Partners Personalized Medicine is the operations driven by information
technology (IT). The same (Laboratory Information Management) LIM systems, which is a software
based management system to support any and all laboratory operations, are utilized across
departments, allowing for end to end project management. These LIMS and the IT infrastructure are
described in depth in “The Information Technology Infrastructure for the Translational Genomics Core
and the Partners Biobank at Partners Personalized Medicine” in this issue. For research projects two
main LIMS are utilized, STARLIMS and GIGPAD. STARLIMS is used to manage sample processing
workflows in the lab. It also serves as a sample inventory tracking system capturing the physical
location of samples within the lab. If investigators have their own external samples to submit for
processing, they can place orders through GIGPAD (https://portal.hpcgg.org/). Investigators can
upload their sample information directly into the portal and order sample processing and analysis
services. The genomic instruments and analysis software in the lab can feed output data directly into
this LIMS allowing data to be viewed and downloaded securely by investigators through this platform.
GIGPAD is also used to bill for rendered services. GIGPAD interfaces with STARLIMS, so updates in
the processing workflow made by the lab in STARLIMS are automatically updated in GIGPAD for the
investigator to view.
The same IT team supports all departments at Partners Personalized Medicine. One of the roles
of the IT team is to manage both GIGPAD and STARLIMS. Having the same team manage both LIMS
helps maintain the integrity of data being shared between the two platforms. This unification of
support also helps streamline troubleshooting for the ongoing clinical and research processes within
Partners Personalized Medicine as well as and external investigators. Members from the lab and IT
teams meet weekly to provide updates, feedback on functionality, and bring any issues to discuss. This
ongoing dialogue helps keep operations running smoothly.
The Partners Biobank houses banked samples (plasma, serum, and DNA) collected from
research-consented patients from Partners Healthcare hospitals, which are available to Partners
researchers or distribution to Partners HealthCare investigators with appropriate approval from
the Partners Institutional Review board (IRB) (described in “The Partners HealthCare Biobank at
Partners Personalized Medicine” article in this issue). Whether samples were obtained through the
Partners Biobank or were from an investigator’s private cohort, the Biobank can provide samples
processing services, such as extraction, quantitation, and plating. The Biobank is proficient at preparing
samples to meet required specifications for various downstream processing platforms offered by the
Translational Genomics Core. Many investigators take advantage of this end to end workflow, and
will submit samples to the Biobank for preparation to be processed by the TGC. The same lab manager
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and project manager oversee projects in both the Biobank and the TGC. This integration between
departments lends to a smooth transition of projects from sample processing to the genomic analysis
stage. The same LIMs and PPM staff track projects from the time the initial request is made, through
sample preparation in the Biobank and genomic analysis in the Translational Genomics Core, until the
return of data. If analysis is requested, the project will be tracked through the Bioinformatics team
until analyzed data is released to the investigator, through a secure File Transfer Protocol (FTP) on the
Partners Healthcare network for Partners Healthcare researchers, or through an external hard drive.
4. Providing Bioinformatics (BioFx) Support on Core Areas of Expertise
Processing and analysis of sequencing and genotyping data requires complex bioinformatics
tools and pipelines to provide reliable results that can be accurately interpreted in the context
of the study. Working closely with the bioinformatics team at PPM, the TGC is able to provide
bioinformatics services and expertise to translational and clinical researchers. Given the enormous
time and effort required to build bioinformatics tools and gain analytical expertise, the TGC has
aligned its bioinformatics development goals and services with that of different components of the
center. For example, leveraging the LMM’s expertise in sequencing analysis, “clinical” grade variant
calling and comprehensive annotation for whole genome/exome and targeted sequencing projects
is offered to researchers through the core. For researchers with limited expertise in the development
of bioinformatics tools, this has led to confidence in analytical methods and efficient utilization of
genomic sequencing data. Although many bioinformatics requests have been encountered, we have
limited our services to focus on those that are more common to investigators at Partners Healthcare
In addition, we have focused our in-house bioinformatics development efforts to support the
technology platforms most utilized by the majority of translational and clinical investigators including:
(1) variant calling and annotation for targeted sequencing panels, exomes, and whole genomes,
(2) differential expression through RNAseq, (3) allele calling on genotyping arrays, and (4) differential
expression on microarray platforms. To this end, our strategy is to partner with research groups with a
vested interest in a given assay or platform. This allows both groups to share resources and expertise
in building an end-to-end solution for novel techniques and platforms. These partnerships often arise
with repeat external users of center resources who want to develop a new experiment protocol that
requires special equipment and expertise for the wet bench portion and is an area of interest in the
research community. We are able to contribute to this partnership by providing the development of
the wet bench process and access to the specialized equipment.
One such example, is the development of a robust whole transcriptome sequencing analysis
pipeline through a collaboration between the TGC and a Partners investigator with training and
expertise in bioinformatics analysis. Through this interaction, the core provided access and technical
expertise in library construction from RNA samples and sequencing of libraries on the NGS platform.
The investigator, in turn, developed an analysis pipeline using the Tuxedo Suite tools (Broad Institute)
that includes alignment of reads to a reference genome, measures transcript abundance, and performs
differential expression analysis and visualization. Through several rounds of validation experiments
and analyses, we optimized our wet-bench and analysis workflow to include quality control (QC)
measures such as synthetic oligo spike-ins and fastq QC analysis which help inform on the quality of
samples and their processing in the lab, and then set “pass” thresholds to avoid the use of inaccurate
data. A copy of this pipeline was transferred to PPM servers and is maintained and offered to other
researchers through our bioinformatics group, providing a laboratory processing workflow with QC
checks at multiple steps and access to a validated transcriptome sequencing analysis pipelines. Similar
initiatives to co-develop bioinformatics tools for platforms and techniques that support personalized
medicine research are underway, including metagenomics 16S rRNA gene microbial profiling and
small RNA/miRNA profiling and discovery from serum and plasma samples.
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5. Supporting Biobank Genotyping Initiative
A major goal of the Partners Personalized Medicine Biobank is the genotyping of Biobank samples
using the MEGArray chip on Illumina’s Infinium platform. To complete objectives of this genotyping
initiative, the TGC is required to meet a throughput of 1000–1500 samples per month to be run on
this chip. Genotyping hardware and infrastructure already existed in the TGC for genotyping small
projects with a low sample number. The increase in volume and throughput required by the Biobank
genotyping project meant that we required additional resources, equipment, modification to existing
equipment and a sample handling and wet lab processing LIMS. The Illumina Laboratory Information
Management System (LIMS) is a proprietary system used to connect sample ID’s in sample plates
with all reagent barcodes and to collect technician and instrument ID’s and timestamps for complete
documentation of the wet lab process from start to finish. Manual collection of this information with
a hand-held barcode scanner was possible but slowed the process dramatically and was liable to
introduce error. This made it necessary to integrate a robotic manipulator arm (RoMa) to the Tecan EVo
liquid handling system (Tecan) for all the post PCR sample handling and manipulation. The RoMa
integrates two barcode scanners necessary for capturing sample, reagent, and chip identity throughout
the process. The capacity of our scanner was doubled by the introduction of a second scanner with
a twister arm to allow walkaway continuous scanning of chips into the LIMS. These improvements
allow processing of 384 samples per week by one technician, with throughput doubling with two
technicians on a staggered schedule.
On completion of scanning the chips, data (.idat) is collected in the Illumina LIMS and a previously
generated cluster file (.egt file) from Illumina GenomeStudio software is applied to it along with a SNP
manifest file specific for the version of the chip used (.bpm). The cluster file assigns an allele call to each
sample per SNP based upon the intensity of the fluorescent dye found at a position on the chip during
scanning. The ID of the SNP is based on the position of the call on the chip using the manifest (.bpm)
as a reference. This produces the genotype call files (GTC) that are used to create smaller binary PED
files. PEDs from each sample are merged together and then curated to remove failing SNPs, which are
SNPs having a call rate <0.95% across all samples, or SNPs that are not mapped to the genome. At this
point the Biobank IDs are re-associated with the data as well as a gender designation. The genotyped
gender is compared to the assigned gender as a QC check. Quality control plots are generated to
allow identification of failing samples; those that are lower than 97% success across all targeted
positions or show an intensity signal lower than the intensity of the background noise. An overview
of the genotyping workflow is shown in Figure 3 which highlights the sample wet bench processing,
integration of the Illumina LIMS and our homebrew GIGPAD LIMS, as well as initial bioinformatics
analyses that offer basic genotyping calls and quality control check based on SNP intensities and/or
call rates. Additional information on the bioinformatics workflow is described in Tsai et al. [1]. For the
TGC, the utility of this integration between the LIMS and Biofx processes is in its ability to perform
cluster file generation using multiple batches run on the same array, thereby enhancing allele calling,
particularly to rare SNPs, and lower the SNP failure rate. In addition, the generation of sample QC
plots for multiple batches simultaneously, which occurs at the “snpqc_info” step in Figure 3 and is
described in Tsai et al. [1], allows the laboratory team to more easily identify failed samples and batch
specific trends relating to sample quality or chip lot quality due to manufacturer error.
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6. Staffing and Operations Challenges at an Academic Core
The field of genomics is a ra idly changing field with the introduction of new technique and
technologi s on a regular basis allowing genomics to b carried out faster and cheap r than previous
iterations. Generally, core labs are forced by budgetary constraints to recruit inexperienced graduates
and train them on the job. Once hired, retention then becomes an issue, as technical staff with growing
experience have the option of moving to higher paying similar roles in surrounding industry labs.
Balancing staffing levels with demand is tricky as volume of incoming work is highly variable with
little long term planning and communication between the researcher and the core lab. High turnaround
of staff and constantly changing services requires close management to ensure the laboratory remains
in GLP (Good Laboratory Practice) compliance [2]. This is an important quality measure for our
custom r , especially those who may be working towards FDA app oval a part of their search.
While success of a core facility can be measured by financial success, in an academic envir nment
another measure of success is through publication, either directly by the core facility or through
recognition of the core within publications by our customers, or the number of grants that a core
facility supports. Following below is a more detailed discussion on how we deal with each of these
challenges with the aim of moving forward within the world of genomics and providing a high quality
cost effective service to our customers.
Our facility’s pool of customers includes a large number of translational and clinical researchers
whose needs are wide ranging in the field of genomics. As well as carrying out internal review of new
technologies and techniques ourselves, we are often approached by customers with novel methods or
instrumentation needs, looking for a service lab to support them. The effort required to bring on a
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new technique is high, so detailed consideration may be required. Technique development demands
resources be redirected from income generating production work for a period of time while manual
testing, optimization, automation of high volume tests, quality control, procedure documentation
and analysis of data is carried out. Other points to consider include availability of staff to carry out
development, acceptable timeline for development of the test for the requesting customer, the level
of demand for a new test, whether proposed cost to customer will be acceptable and if there are
cheaper alternative services available to researchers in other institutional facilities. Introduction of
new instrumentation is also high risk, due to the potentially high purchase price. Caution may be
warranted to allow time to monitor how well that technology performs in other facilities. If possible,
alternative systems should be reviewed to ensure the correct decision is made. Proof of concept testing
is required, either with the vendor of the instrumentation or with a known collaborator/colleague.
One way for a core facility to mitigate the burden of the instrument purchase price is to partner with a
PI or consortium who hold a grant to cover the purchase of a high value instrument and offer to house
and operate the instrumentation for a reduced fee, while allowing other customers’ samples to be run
on that instrument in downtime. At the opposite end of the spectrum, the decision to stop offering
a technique or use of piece of instrumentation, sometimes when there is still low demand for it, is
made to offset unnecessary expenditure of resources, labor, and costs associated with maintaining that
platform or process.
The largest three items in our annual budget are supplies, maintenance contracts and salaries.
Supply costs can be negotiated with vendors for best prices, but they also vary with volume. The costs
of supplies are covered directly by charges to our customers. Maintenance contracts are more static
but can also be negotiated with cheaper contracts arising by locking down coverage over multiple
years. Salaries are defined on an institutional level depending on qualifications and experience to
ensure parity over staff at a particular level within the institution. This makes it difficult to compete
in salary for outstanding new hires. Our current staff includes a Director, a Laboratory Manager, a
Project Manager and five junior staff. All junior staff are hired with no experience and go through
lengthy training on the job, so in order to make this worthwhile we ask for two years as a minimum
commitment. There can be hesitancy in accepting a position within a core facility as there is an
incorrect perception of the scope of work carried out by junior staff in a fee-for–service lab. Prior to
working in our lab, the perception is that it would be mundane, boring and repetitive, but in reality
all staff are cross trained on all our services through genotyping, next-generation sequencing and
gene expression and so are kept busy and challenged. In addition, during the interviewing process
we highlight the broad range of cutting edge clinical and translational research that we are involved
in to off-set the negative perception of working in a “core” laboratory. This has attracted junior
technicians who are exploring career paths or considering graduate or professional education, who felt
the scope and breadth of work done at the TGC will be helpful for their respective goals. However,
because of the cutting edge nature of the techniques we use, we do find we have an issue with staff
retention. The experience gained by our junior staff is sought after by many of the surrounding private
institutions and we find that we lose staff after two years due to more competitive salaries offered by
those institutions. We aim to attract high quality junior staff and prevent loss of exceptional staff by
promotion based on ability, and by giving ownership of interesting and varied projects. This allows
them to gain skills in project design, customer service, time management, research and development,
as well as management of more junior staff. We also allow time for the staff to take advantage of the
professional development training classes offered by our institution. Another thing that we promote is
to have our senior management engage with our junior staff and provide recognition for good quality
work. We hope that these benefits provided to our staff are giving them experience and education that
will hold them in good stead to be successful as they move into their next role, whether that is in our
lab or out of it.
The aim of Good Laboratory Practice (GLP) of the food and drug administration (FDA) is to
provide consistently high quality technical work and data over time and over different technical
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staff. There are many areas covered by GLP including equipment management, training records,
standard operating procedures, materials quality, data management and quality processes as detailed
in 21 CFR 58 [2]. The challenge for any lab is the vast amount of organization and documentation to
establish and maintain GLP. It requires buy in and input from all members of staff, so they must all
receive the necessary GLP training. It is important that all staff see how following GLP regulations
can improve the quality of data we generate for our customers. The biggest challenge we face is
the amount of time we can dedicate to the implementation of GLP. Due to our small staff size and
the large range of available services, we have limited resources to devote to this as the bulk of our
effort is put towards the production of data to our customers. We have initiated GLP compliance in
our lab for certain core services such as next generation sequencing and Infinium array genotyping,
and are in the process of working through each of our services and understand that this process
may take several years. A published study into University GLP compliance showed that the average
years to compliance was four years, ranging from 10 months to seven years [3]. This study identifies
several challenges to GLP compliance related to the management of GLP programs, quality assurance
training and implementation for technicians, and inadequate documentation of all processes within a
GLP workflow [3].
One of the measures of success and progress of an academic lab is the production of journal
articles. This measure is also true in the case of a Core facility; we monitor publications from our
institution on a regular basis to aid in measuring the usage of our facility. In the past, it has been
common to find that our facility has not been acknowledged, so we remind our customers on data
delivery that an acknowledgement is very much appreciated. This process is becoming more common
amongst Core facilities and has been recognized as an issue at several national conferences (NERG
and ABRF) and highlighted in an editorial in BioTechniques [4]. However, an alternative measure
of success has been to identify the number of grants or grant dollars supported by our laboratories.
Our figures for the 2014–2015 academic year show that we have supported over 60 grants totaling over
$165 million.
7. Conclusion
Our operational experiences highlight common considerations encountered at academic research
core such as evolving with the advancement of genomic and transcriptomic technologies and assays,
and responding to the diverse needs of investigators at an academic and clinical research institution.
As highlighted in this article, several key components have allowed us to thrive in this environment,
including: (1) building a core set of genomics and bioinformatics services developed through
partnerships and collaborations with a clinical lab or researchers within the institution, (2) having a
broad and flexible LIMS system that can handle the tracking and management of variety of sample
and library types and can easily adapt and integrate new technologies, and (3) cross training of junior
staff across multiple platforms and techniques to engage current staff and limit the impact of staff
turnover on productivity. As many academic research cores are fee-for-service with limited funds for
development and validation of new workflows and implementing regulatory compliance for current
ones, the decision to pursue these initiatives must be weighed against the impact it will have on current
production and productivity, and the perceived added benefit of that endeavor. These will not always
be clear to research cores, which emphasizes the importance of building relationships with clinical and
research labs within the institution.
The integrative nature of all the components of Partners Personalized Medicine situates the
Translational Genomics Core in a unique position among academic core laboratories. This is reinforced
by a seamless integration of IT infrastructure and bioinformatics pipelines to allow easy communication,
management and tracking of samples and data for both external researchers and PPM research
initiatives. The Biobank genotyping initiative, which involves Partners Biobank samples, LIMS
infrastructure supporting both the Biobank and the TGC, as well bioinformatics pipelines for quality
check steps and analysis, highlights the seamless integration of different components for an efficient
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workflow at the TGC. As such, the TGC is able to utilize its interactions within the center to offer
end-to-end genomic analyses services to academic and clinical researchers, while ensuring that
onboarding of novel platforms and assays can rapidly occur to help meet the goals of the center.
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